Mesa Laboratories, Inc.: financial statements

MLABNASDAQIndustrials · Industrial Instruments For Measurement, Display, and Control

Price

$134.09

November 16, 2026Market cap $741M

What Ploutos Investor adds for Mesa Laboratories

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2024–FY2026 fiscal years

Click a line to see it on the chart.

Revenue

LineFY2024FY2025FY2026Average a year
Revenue $216M$241M$249M
Cost of revenue $83M$90M$91M
Gross profit $133M$151M$158M
Operating income -$272M$16M$19M
Net income -$254M-$2.0M$6.7M
Earnings per share -$47.20-$0.36$1.21
Earnings per share, basic -$47.20-$0.36$1.22
Margins
Gross margin 61.6%62.6%63.5%
Operating margin -125.9%6.8%7.4%
Net margin -117.6%-0.8%2.7%

Financial statements

MLAB's revenue, profits and cash flows from FY2011 to FY2023, 13 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2024: Sterilization And Disinfection Control $75M, Calibration Solutions $48M, Biopharmaceutical Development $41M, Clinical Genomics $53M
  • FY2025: Sterilization And Disinfection Control $93M, Calibration Solutions $52M, Biopharmaceutical Development $49M, Clinical Genomics $47M
  • FY2026: Sterilization And Disinfection Control $102M, Calibration Solutions $54M, Biopharmaceutical Development $49M, Clinical Genomics $45M
SegmentFY2024FY2025FY2026Share FY2026
Sterilization And Disinfection Control$75M$93M$102M41%
Calibration Solutions$48M$52M$54M21%
Biopharmaceutical Development$41M$49M$49M20%
Clinical Genomics$53M$47M$45M18%

By segment

MLAB's revenue by segment from FY2014 to FY2023, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$11M Due within 2 years$17M Leases44.1% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

When the debt falls due

Mar 31, 2026

Due within 2 years

$11M

Principal of loans and bonds falling due, from the annual report dated March 31, 2026, without leases and interest. The filing

  • 3/2027: $5.6M
  • 3/2028: $5.6M

Leases

Mar 31, 2026

Operating leases

$17M

Finance leases

–

The liability is the present value of the rent still to pay, at March 31, 2026. It is not counted in the ladder's debt. The filing

Goodwill by segment

Mar 31, 2026

Total goodwill

$187M

  • Sterilization and Disinfection Control$83M44%

Goodwill is what the company paid in acquisitions above the value of what it bought, at March 31, 2026. If an acquisition earns less, the goodwill is impaired and earnings fall. The filing

$187MTotal goodwill

From the statutory to the effective tax rate, FY2026

Mar 31, 2026

Statutory rate

21.0%

Effective rate

44.1%

+23.1 pts

The company paid 44.1% in tax on its profit, 23.1 points above the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Share-based compensation

+23.4 pts

Difference the filing does not itemize

-0.3 pts

Effective rate

44.1%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

Other than debt, no claim large enough to list ranks ahead of the shares.

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 16, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +2.6% on the same quarter a year earlier, and receivables -1.8%. Inventory was -4.3%, against -4.1% for the cost of sales.

a year earlier 60 days
58 days
a year earlier 108 days
108 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Allowance for doubtful accounts

The allowance for receivables that may not be collected was 4.6% of gross receivables at Sep 30, 2026, against 4.4% a year earlier.

a year earlier $1.8M
$1.9M

Taxes: deferred and paid

The deferred part was -24.2% of the tax charge in the year to Mar 31, 2026. The rows show the last 2 years.

Cash taxes paid were 28.4% of the current tax charge in the year to Mar 31, 2026.

  • Cash taxes paid against the current charge are lower than at nine in ten S&P 500 companies.
Deferred share, year to Mar 31, 2026-$1.3M of $5.3M
-24.2%
Deferred share, year to Mar 31, 2025-$61.0K of $7.9M
-0.8%
$1.9M paid, $6.6M current
28.4%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Mesa Laboratories's filings show?

These are Mesa Laboratories's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MLAB's financials

Didn't find what you were looking for?

Ask us
How much revenue did MLAB have in FY2026?

Mesa Laboratories had revenue of $249M and net income of $6.7M in fiscal FY2026, a net margin of 2.7%.

How much debt does MLAB have?

On March 31, 2026 Mesa Laboratories had total assets of $428M, debt of $68M and shareholders' equity of $186M.

How much free cash flow does MLAB have?

In fiscal FY2026 Mesa Laboratories had cash from operations of $43M and spent $3.3M on capital expenditure, leaving $40M of free cash flow.

Where are the figures from?

From Mesa Laboratories, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.